Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹274.55
18.60 (7.27%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹959 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
13.5
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹161.5+70.0%
52W High₹320.95-14.5%
Current Price
₹274.55
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹219.64
Upper Circuit₹329.46
Reference Price
₹274.55
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹326.4
Double Bottom on 1D (BREAKOUT CONFIRMED) — target ₹326.4
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 41.7 (BUY) with 53.3% confidence
10/20 Bearish Cross detected 3 day(s) ago
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
53%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
265.61
EMA50
260.43
EMA200
254.61
Price Action
MIXED
NEUTRAL
Higher Highs4
Higher Lows5
Lower Highs5
Lower Lows4
Support & Resistance Levels
Resistance (Above)
₹278.62
₹286.84
₹309.00
₹315.20
₹320.95
Support (Below)
₹274.20
₹266.20
₹259.15
₹245.38
₹236.38
Volume Analysis
TrendINCREASING
Change+119.70%
Unusual VolumeNo
Recent MA Crossovers
10/20 Bearish Cross
3 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹271.80
3% Risk₹266.31
5% Risk₹260.82
7% Risk (Custom)
₹255.33Technical Levels
1x ATR (Volatility)₹259.05
2x ATR (Swing)₹243.55
3x ATR (Trend)₹228.05
Immediate Support₹274.20
Moving Averages
EMA 9 (Short-term)₹264.90
EMA 20 (Medium-term)₹265.61
EMA 50 (Trend)₹260.43
EMA 200 (Long-term)₹254.61
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹172 Cr | ₹163.2 Cr | ₹160.1 Cr | ₹162.4 Cr |
| Net Profit | ₹20.3 Cr | ₹13.5 Cr | ₹15.2 Cr | ₹15.8 Cr |
| EPS | — | ₹4.12 | ₹4.58 | ₹4.52 |
| Operating Profit | ₹31.5 Cr | ₹24.8 Cr | ₹26 Cr | ₹26.9 Cr |
ROE
51.51%
ROCE
28.16%
Debt/Equity
2.98
Current Ratio
1.11
OPM
16.54%
NPM
9.70%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 20 Sept 2024 | Annual General Meeting | AGM |
| 10 Nov 2023 | Extra Ordinary General Meeting | OTHERS |
| 20 Sept 2023 | Annual General Meeting | AGM |
| 14 Aug 2023 | Extra-Ordinary General Meeting | OTHERS |
| 20 Sept 2022 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for WANBURY
View AllNEWS
positive
Business Standard - Markets 3d ago
Wanbury explores new market opportunities for its new APIs
Receives Korea FDA approval for its Patalganga facility
WANBURYHealthcare
NEWS
neutral
Business Standard - Markets 12d ago
Wanbury standalone net profit rises 7.11% in the March 2026 quarter
Sales decline 4.31% to Rs 164.58 crore
WANBURYHealthcare